JP2022548226A5 - - Google Patents
Info
- Publication number
- JP2022548226A5 JP2022548226A5 JP2022515885A JP2022515885A JP2022548226A5 JP 2022548226 A5 JP2022548226 A5 JP 2022548226A5 JP 2022515885 A JP2022515885 A JP 2022515885A JP 2022515885 A JP2022515885 A JP 2022515885A JP 2022548226 A5 JP2022548226 A5 JP 2022548226A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- composition
- approximately
- concentration
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962900060P | 2019-09-13 | 2019-09-13 | |
| US62/900,060 | 2019-09-13 | ||
| US202063044288P | 2020-06-25 | 2020-06-25 | |
| US63/044,288 | 2020-06-25 | ||
| PCT/US2020/050565 WO2021051003A1 (en) | 2019-09-13 | 2020-09-11 | Ophthalmic formulations of methotrexate |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022548226A JP2022548226A (ja) | 2022-11-17 |
| JP2022548226A5 true JP2022548226A5 (enExample) | 2023-09-20 |
| JP7682512B2 JP7682512B2 (ja) | 2025-05-26 |
Family
ID=74866765
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022515885A Active JP7682512B2 (ja) | 2019-09-13 | 2020-09-11 | メトトレキサートの眼科用製剤 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US12005060B2 (enExample) |
| EP (1) | EP4028015A4 (enExample) |
| JP (1) | JP7682512B2 (enExample) |
| KR (1) | KR20220062617A (enExample) |
| CN (1) | CN114423432A (enExample) |
| AU (1) | AU2020344685A1 (enExample) |
| CA (1) | CA3149467A1 (enExample) |
| IL (1) | IL291228A (enExample) |
| WO (1) | WO2021051003A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011072141A1 (en) | 2009-12-11 | 2011-06-16 | Neuron Systems, Inc. | Compositions and methods for the treatment of macular degeneration |
| CN117045653A (zh) | 2013-01-23 | 2023-11-14 | 奥尔德拉医疗公司 | 与毒性醛相关的疾病和治疗 |
| US10550085B2 (en) | 2015-08-21 | 2020-02-04 | Aldeyra Therapeutics, Inc. | Deuterated compounds and uses thereof |
| AU2019319740A1 (en) | 2018-08-06 | 2021-03-25 | Aldeyra Therapeutics, Inc. | Polymorphic compounds and uses thereof |
| JP2022530967A (ja) | 2019-05-02 | 2022-07-05 | アルデイラ セラピューティクス， インコーポレイテッド | 多形化合物およびその使用 |
| WO2020223717A1 (en) | 2019-05-02 | 2020-11-05 | Aldeyra Therapeutics, Inc. | Process for preparation of aldehyde scavenger and intermediates |
| EP4028015A4 (en) | 2019-09-13 | 2023-11-15 | Aldeyra Therapeutics, Inc. | Ophthalmic formulations of methotrexate |
| WO2021231792A1 (en) | 2020-05-13 | 2021-11-18 | Aldeyra Therapeutics, Inc. | Pharmaceutical formulations and uses thereof |
| US11911385B1 (en) | 2022-12-14 | 2024-02-27 | Aldeyra Therapeutics, Inc. | Methotrexate treatment methods |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040253243A1 (en) | 2003-01-21 | 2004-12-16 | David Epstein | Aptamer therapeutics useful in ocular pharmacotherapy |
| US20050255144A1 (en) | 2003-04-09 | 2005-11-17 | Directcontact Llc | Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases |
| WO2005065079A2 (en) | 2003-11-10 | 2005-07-21 | Angiotech International Ag | Medical implants and fibrosis-inducing agents |
| US20050244469A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Extended therapeutic effect ocular implant treatments |
| KR101341359B1 (ko) | 2004-10-01 | 2013-12-13 | 램스코르 인코포레이티드 | 편리하게 이식가능한 서방형 약물 조성물 |
| DK1848431T3 (en) * | 2005-02-09 | 2016-04-18 | Santen Pharmaceutical Co Ltd | LIQUID FORMULATIONS FOR TREATMENT OF DISEASES OR CONDITIONS |
| CA2606226A1 (en) | 2005-04-27 | 2006-11-02 | University Of Florida Research Foundation, Inc. | Materials and methods for enhanced degradation of mutant proteins associated with human disease |
| US20060257391A1 (en) | 2005-05-11 | 2006-11-16 | Bausch & Lomb Incorporated | Non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy and the treatment of other ocular conditions |
| US20090081277A1 (en) | 2007-09-21 | 2009-03-26 | Allergan, Inc. | Pharmaceutical formulations and methods for treating ocular conditions |
| WO2010047803A2 (en) | 2008-10-22 | 2010-04-29 | Oncotx, L.L.C. | A method for the treatment of proliferative disorders of the eye |
| AU2010221438C1 (en) | 2009-03-03 | 2015-01-29 | Alcon Research, Ltd. | Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (RTKi) compounds to the eye |
| GB201200192D0 (en) * | 2012-01-06 | 2012-02-22 | Rosemont Pharmaceuticals Ltd | Methotrexate composition |
| EP2890389A1 (en) * | 2012-08-28 | 2015-07-08 | Novartis AG | Use of a vegf antagonist in treating ocular vascular proliferative diseases |
| US20140105956A1 (en) | 2012-10-11 | 2014-04-17 | Rupak BANERJEE | Biodegradable polymer based microimplant for ocular drug delivery |
| MX373894B (es) | 2012-11-08 | 2020-07-09 | Clearside Biomedical Inc | Métodos y dispositivos para el tratamiento de trastornos oculares en sujetos humanos. |
| ES2969374T3 (es) * | 2014-07-30 | 2024-05-17 | Massachusetts Eye & Ear Infirmary | Metotrexato para la vitreorretinopatía proliferativa |
| GB201419261D0 (en) * | 2014-10-29 | 2014-12-10 | Therakind Ltd | Formulations |
| GB201522441D0 (en) | 2015-12-18 | 2016-02-03 | Midatech Pharma Wales Ltd | Sustained release cyclosporine-loaded microparticles |
| WO2018201146A1 (en) | 2017-04-28 | 2018-11-01 | Case Western Reserve University | Compounds and methods of treating retinal degeneration |
| EP3759072A4 (en) | 2018-03-01 | 2021-11-03 | The Trustees of Columbia University in the City of New York | COMPOUNDS, COMPOSITIONS AND METHODS FOR RELATING TOXIC STRESS FROM ENDOPLASMIC RETICULUM |
| EP4028015A4 (en) | 2019-09-13 | 2023-11-15 | Aldeyra Therapeutics, Inc. | Ophthalmic formulations of methotrexate |
| AU2021225926A1 (en) | 2020-02-26 | 2022-10-20 | Case Western Reserve University | Compositions and methods for treating misfolded protein ocular disorders |
-
2020
- 2020-09-11 EP EP20863798.3A patent/EP4028015A4/en active Pending
- 2020-09-11 CA CA3149467A patent/CA3149467A1/en active Pending
- 2020-09-11 AU AU2020344685A patent/AU2020344685A1/en not_active Abandoned
- 2020-09-11 KR KR1020227012402A patent/KR20220062617A/ko not_active Ceased
- 2020-09-11 JP JP2022515885A patent/JP7682512B2/ja active Active
- 2020-09-11 CN CN202080063801.6A patent/CN114423432A/zh active Pending
- 2020-09-11 WO PCT/US2020/050565 patent/WO2021051003A1/en not_active Ceased
-
2022
- 2022-03-09 IL IL291228A patent/IL291228A/en unknown
- 2022-09-15 US US17/932,426 patent/US12005060B2/en active Active
- 2022-09-15 US US17/932,453 patent/US12005061B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022548226A5 (enExample) | ||
| AU2015257651B2 (en) | Compounds for treating ophthalmic diseases and disorders | |
| JP7682512B2 (ja) | メトトレキサートの眼科用製剤 | |
| JP6700348B2 (ja) | 持続型薬物送達インプラント | |
| ES2345018T3 (es) | Composiciones y procedimientos para tratar el segmento posterior del ojo. | |
| Gan et al. | Intravitreal dexamethasone as adjuvant in the treatment of postoperative endophthalmitis: a prospective randomized trial | |
| JP2014014694A (ja) | 血管拡張薬を含有する持続放出性眼内インプラント | |
| KR20070057698A (ko) | 이성 감염의 국소 치료 또는 예방을 위한 국소 이성 조성물및 방법 | |
| JP2020536067A5 (enExample) | ||
| JP2021059554A (ja) | 増殖性硝子体網膜症用メトトレキサート | |
| JP2020117522A (ja) | 徐放性医薬組成物 | |
| CN107708738A (zh) | 含有柠檬酸酯的贮库制剂 | |
| JP2007509952A (ja) | ロテプレドノールエタボネートおよびトブラマイシンの局所眼科用懸濁液 | |
| RU2006124557A (ru) | Композиции и способы введения средств, связывающих тубулин, для лечения глазных заболеваний | |
| JP2021152002A5 (enExample) | ||
| JP2024516003A5 (enExample) | ||
| TW202519198A (zh) | 治療糖尿病黃斑水腫的方法 | |
| Watanabe et al. | A Case of Corneal Endothelial Cell Loss After PreserFlo MicroShunt Implantation Requiring Device Removal and Ahmed Glaucoma Valve Implantation With Tube Insertion Into the Vitreous Cavity | |
| Nahata et al. | Candida endophthalmitis associated with total parenteral nutrition | |
| Miserocchi et al. | Treatment of Intermediate Uveitis | |
| RU2025122399A (ru) | Способ лечения операционных осложнений при хирургическом лечении катаракты | |
| CN121925262A (zh) | 多黏菌素b/甲氧苄啶与利福平的增强型制剂及其眼部应用方法 | |
| Escott et al. | Medical Management of CME Associated with Uveitis | |
| JP2022545553A5 (enExample) | ||
| HK40092417A (zh) | 用於治疗眼科疾病和障碍的化合物 |